Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VCYT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVeracyte reports Q2 2026 revenue $150.3M (+15% YoY), raises FY2026 guidance
Filed July 30, 2026 · Period ending July 30, 2026 · ~1 min read
Key Changes
-
high
Q2 2026 total revenue $150.3M (+15% YoY), testing revenue $145.7M (+19%); Decipher $91.9M (+20%), Afirma $51.2M (+18%). Test volume up 13% to 50,967 tests.
Exhibit 99.1 view on EDGAR → -
high
GAAP net income $25.5M (17.0% margin), adjusted EBITDA $44.0M (29.2% margin). Operating cash flow $45.8M; cash and investments $485.2M at quarter-end.
Exhibit 99.1 view on EDGAR → -
high
Raised FY2026 total revenue guidance to $590–$596M (14–15% growth) from $582–$592M; testing revenue to $576–$582M (17–18% growth) from $570–$580M. Maintained adjusted EBITDA margin target >26%.
Exhibit 99.1 view on EDGAR → -
high
Launched Prosigna Breast Test (early-stage HR+ breast cancer) and TrueMRD Monitoring Test (muscle-invasive bladder cancer). Secured first Medicare coverage for whole-genome sequencing-based TrueMRD platform.
Exhibit 99.1 view on EDGAR → -
medium
Q2 2026 GAAP gross margin improved to 72% from 69% YoY; non-GAAP gross margin 75% vs. 72%. GAAP operating expenses declined to $85.6M from $95.0M; non-GAAP opex grew 16% to $70.0M.
Exhibit 99.1 view on EDGAR →
Summary
Veracyte reported strong second-quarter 2026 results, with total revenue of $150.3 million (up 15% year-over-year) and testing revenue of $145.7 million (up 19%). The company's two core franchises drove growth: Decipher prostate testing revenue rose 20% to $91.9 million on 17% volume growth, while Afirma thyroid testing revenue increased 18% to $51.2 million on 10% volume growth.
Profitability improved materially, with GAAP net income of $25.5 million (17.0% margin) and adjusted EBITDA of $44.0 million (29.2% margin). The company generated $45.8 million in operating cash flow and ended the quarter with $485.2 million in cash and investments.
Veracyte raised its full-year 2026 revenue guidance to $590–$596 million (14–15% growth) from prior guidance of $582–$592 million, and increased testing revenue guidance to $576–$582 million (17–18% growth) from $570–$580 million, excluding contributions from recently launched tests. The company maintained its adjusted EBITDA margin target above 26%. The quarter also saw two product launches—Prosigna Breast Test for early-stage HR+ breast cancer and TrueMRD Monitoring Test for muscle-invasive bladder cancer—and the company secured Medicare coverage for TrueMRD, the first such decision for its whole-genome sequencing platform. Gross margin expansion (72% GAAP, 75% non-GAAP) reflects improving operating leverage as the testing business scales.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Veracyte announced Q2 2026 financial results via press release.
Added in current filing · verify on EDGAR →
On July 30, 2026, Veracyte, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026.
Veracyte disclosed its second quarter 2026 financial results through a press release. The 8-K body does not contain specific financial figures; those would be in the attached Exhibit 99.1 press release.
Event · Exhibit 99.1
Veracyte reported Q2 2026 results: total revenue $150.3M (+15% YoY), testing revenue $145.7M (+19%), GAAP net income $25.5M, and raised FY2026 guidance.
Added in current filing · view on EDGAR →
Increased total revenue by 15% to $150.3 million and testing revenue by 19% to $145.7 million, driven by Decipher growth of 20% to $91.9 million and Afirma growth of 18% to $51.2 million.
•Increased total volume by 13% to 50,967 tests and testing volume by 14% to 48,389 tests, driven by Decipher growth of 17% to approximately 29,700 tests and Afirma growth of 10% to approximately 18,600 tests.
Veracyte's Q2 2026 total revenue reached $150.3 million, up 15% year-over-year, with testing revenue growing 19% to $145.7 million. The Decipher prostate test contributed $91.9 million (up 20%) and Afirma thyroid test $51.2 million (up 18%). Total test volume rose 13% to 50,967 tests, with Decipher volume up 17% to ~29,700 tests and Afirma up 10% to ~18,600 tests.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 31, 2026 · How we verify